IMSCIV

Immunogenicity of Mesenchymal Stem Cells in vivo

Coordinatore	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD    more  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Ms. Nome: Linda Cognome: Pialek Email: send email Telefono: +44 1 865289811 Fax: +44 1 865289801
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	170˙733 €
EC contributo	170˙733 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-IEF-2008
Funding Scheme	MC-IEF
Anno di inizio	2009
Periodo (anno-mese-giorno)	2009-04-01   -   2011-03-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD  Organization address address: University Offices, Wellington Square city: OXFORD postcode: OX1 2JD contact info Titolo: Ms. Nome: Linda Cognome: Pialek Email: send email Telefono: +44 1 865289811 Fax: +44 1 865289801	UK (OXFORD)	coordinator	170˙733.61

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The immunogenicity of allogeneic mesenchymal stem cells (MSC) and their differentiated progeny in vivo under regular or inflammatory conditions will be addressed using established mouse models of allorecognition and spontaneous autoimmune diabetes. Survival and homing of MSC in vivo in syngeneic and allogeneic recipients will be investigated by tracking MSC. Allorecognition of mouse MSC in vivo will be assessed using CD8 T cells from BM3 T cell receptor transgenic mice, which specifically recognise the MHC class I molecule H2Kb. The importance of antigen presenting cells (APC) and helper T cells in allorecognition of allogeneic MSC in vivo will also be examined. The non obese diabetic (NOD) mouse model will allow investigation of the immunogenicity of MSC in vivo in an inflammatory environment. The effect of IFN-gamma activation of MSC prior to in vivo transplantation into NOD mice will determine the role of this cytokine in the development of a hypo-immunogenic phenotype of MSC in vivo. The reparative and immunosuppressive ability of MSC, activated MSC and insulin producing islet-like differentiated MSC in autoimmune diabetes in vivo will be assessed using the NOD mouse.'